Oric Pharmaceuticals stock maintained at Buy by BTIG, $26 target

BTIG maintained a Buy rating and $26.00 price target on Oric Pharmaceuticals (ORIC) after its Q3 earnings. The stock trades at $7.52, near its 52-week low. The company reported positive data for rinzimetostat and enozertinib, with key trials expected in 2027. ORIC has $345M in cash, sufficient for operations into 2028. Stifel also raised its price target to $18.

Original reporting
Published Nov 17, 2026, 12:24 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 17, 2026, 12:27 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefEarnings
Primary signal
$ORIC
Bullish
medium confidence
Mentioned
$ORIC
Relevance
6/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$ORICBullishMed
01

Why it matters

The piece frames ORIC’s Q3 earnings follow-through as de-risking via clinical data and pushes major trial milestones into 2027, while highlighting a cash position intended to fund operations into 2H 2028.

02

Market read

For ORIC traders, the actionable takeaway is the reinforced catalyst calendar (Q1 2027 topline, H1 2027 phase 3 initiation) and the cash runway supporting funding through 2H 2028.

03

What to watch

The article emphasizes cash runway into 2H 2028, but does not quantify burn rate or dilution risk; traders may need to monitor financing needs if trial timelines slip.

Relevance 6/10Novelty 5/10Timing: post-Q3 earnings, catalyst windows into Q1 2027 and H1 2027

Background

Oric Pharmaceuticals is advancing rinzimetostat (metastatic castration-resistant prostate cancer) and enozertinib (EGFR atypical NSCLC), with MEVPRO-1 and Redwood-1 as key upcoming milestones.

Company-level read

Ticker impact

$ORICBullishMedium confidence
Context

BTIG maintained a Buy on ORIC after its Q3 earnings, citing rinzimetostat progression-free survival data and updated MEVPRO-1 and Redwood-1 timelines.

Expected impact

Likely upward bias as traders price in 2027 topline and phase 3 initiation milestones referenced in the earnings follow-through.

Evidence & confidence

The article ties ORIC’s own reported clinical data and cash runway into specific 2027 catalyst windows, but it is still an analyst-maintenance writeup rather than a fresh primary disclosure beyond the earnings-linked update.

Market effects

Adds incremental sentiment to oncology biotech names tied to prostate cancer and EGFR atypical NSCLC, but impact is company-specific.

Limited, US small/mid-cap biotech sentiment only.

Low, as the catalysts are company-specific clinical timelines and conference-linked data.

Counterpoint

Timeline shifts (MEVPRO-1 to Q1 2027, Redwood-1 into H1 2027) can delay near-term valuation catalysts, leaving the stock vulnerable to trial execution risk.

Key entities

  • Oric Pharmaceuticals

    NASDAQ-listed biotech advancing rinzimetostat and enozertinib; subject of BTIG Buy and $26 target after Q3 earnings.

  • BTIG

    Maintained Buy rating and $26 price target on ORIC.

  • Stifel

    Raised price target to $18 and maintained Buy rating on ORIC.

Related articles

$ORICMed

Wedbush reiterates Oric Pharmaceuticals stock rating on trial data

Wedbush reiterated an Outperform rating and $14.00 price target for ORIC Pharmaceuticals (ORIC) after its Q3 2026 earnings update. The stock is near its 52-week low at $7.52. InvestingPro values ORIC at $8.57. The company shared positive trial data for rinzimetostat in prostate cancer, with Phase 3 studies ongoing. BTIG and Stifel also issued Buy ratings with higher price targets.

$ORICMedAI 8/10

ORIC® Pharmaceuticals Reports Third Quarter 2026 Financial Results and Provides Operational and Rinzimetostat Program Updates

Oric Pharmaceuticals, Inc. (ORIC) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 ORIC ® Pharmaceuticals Reports Third Quarter 2026 Financial Results and Provides Operational and Rinzimetostat Program Updates Initiated Himalayas-1 global Phase 3 trial in patients with mCRPC previously treated with abiraterone, supported by a clinical trial collabo